Lantern Pharma Stock Revenue
| LTRN Stock | USD 6.81 0.33 5.09% |
Lantern Pharma fundamentals help investors to digest information that contributes to Lantern Pharma's financial success or failures. It also enables traders to predict the movement of Lantern Stock. The fundamental analysis module provides a way to measure Lantern Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lantern Pharma stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 0.00 | 0.00 |
Lantern | Revenue |
Lantern Pharma Company Revenue Analysis
Lantern Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Lantern
Projected quarterly revenue analysis of Lantern Pharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Lantern Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Lantern Pharma's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Lantern Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Lantern Pharma reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Lantern Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lantern Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lantern Pharma could also be used in its relative valuation, which is a method of valuing Lantern Pharma by comparing valuation metrics of similar companies.Lantern Pharma is currently under evaluation in revenue category among related companies.
Lantern Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lantern Pharma from analyzing Lantern Pharma's financial statements. These drivers represent accounts that assess Lantern Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lantern Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 93.7M | 119.8M | 87.0M | 65.5M | 46.4M | 92.6M | |
| Enterprise Value | 92.4M | 100.6M | 35.7M | 28.4M | 24.7M | 23.5M |
Lantern Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lantern Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lantern Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lantern Pharma's value.| Shares | State Street Corporation | 2023-12-31 | 27.8 K | Bank Of New York Mellon Corp | 2023-12-31 | 26.5 K | Ubs Group Ag | 2023-12-31 | 26 K | Blackrock Inc | 2023-12-31 | 20 K | Meridian Wealth Management, Llc | 2023-12-31 | 19.7 K | Northern Trust Corp | 2023-12-31 | 12.6 K | Sigma Planning Corp | 2023-12-31 | 11.9 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 11.8 K | Wells Fargo & Co | 2023-12-31 | 4.5 K | Vanguard Group Inc | 2023-12-31 | 365.3 K | Goss Wealth Management Llc | 2023-12-31 | 166 K |
Lantern Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 32.08 M | ||||
| Shares Outstanding | 10.76 M | ||||
| Shares Owned By Insiders | 15.04 % | ||||
| Shares Owned By Institutions | 22.39 % | ||||
| Number Of Shares Shorted | 484.3 K | ||||
| Price To Book | 1.68 X | ||||
| EBITDA | (17.7 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Short Ratio | 1.18 X | ||||
| Earnings Per Share | (1.47) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 73.27 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
| Net Asset | 43.65 M |
About Lantern Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lantern Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lantern Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lantern Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lantern Pharma Piotroski F Score and Lantern Pharma Altman Z Score analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Lantern Stock analysis
When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.